Close Menu

NEW YORK (GenomeWeb) – Veracyte said today that Anthem has issued a positive coverage policy for its Afirma gene expression classifier (GEC) for use in thyroid cancer diagnosis.

The genomic test is designed to identify benign thyroid nodules in patients with indeterminate fine needle aspiration biopsy results. With the coverage policy, it is now available to Anthem's approximately 40 million members, Veracyte said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.